230 related articles for article (PubMed ID: 32346288)
1. Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice.
Ding B; Kallenbach L; Slipski L; Wilk A; O'Brien D; Guranlioglu D
Int J Chron Obstruct Pulmon Dis; 2020; 15():775-786. PubMed ID: 32346288
[TBL] [Abstract][Full Text] [Related]
2. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
3. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β
Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():231-245. PubMed ID: 36908830
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β
Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Duarte M; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
[TBL] [Abstract][Full Text] [Related]
6. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
9. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
11. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
12. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
13. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
[TBL] [Abstract][Full Text] [Related]
14. Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B
Czira A; Banks V; Requena G; Wood R; Tritton T; Wild R; Compton C; Ismaila A
BMJ Open; 2024 Feb; 14(2):e072361. PubMed ID: 38326272
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
Strange C; Walker V; DePietro M; Tong J; Kurlander J; Carlyle M; Millette LA; Wittbrodt E
Int J Chron Obstruct Pulmon Dis; 2019; 14():1377-1388. PubMed ID: 31303751
[No Abstract] [Full Text] [Related]
16. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
Nagar S; Patel J; Stanford RH
Manag Care; 2018 May; 27(5):40-47. PubMed ID: 29763411
[TBL] [Abstract][Full Text] [Related]
17. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
18. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
Hahn B; Hull M; Blauer-Peterson C; Buikema AR; Ray R; Stanford RH
Respir Med; 2018 Jun; 139():65-71. PubMed ID: 29858004
[TBL] [Abstract][Full Text] [Related]
19. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
Lane DC; Stemkowski S; Stanford RH; Tao Z
J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study.
Suissa S; Dell'Aniello S; Ernst P
COPD; 2021 Feb; 18(1):1-8. PubMed ID: 33569990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
